PTO/SB/08B (04-03)
Approved for use through 04/30/2003: OMB 0651-0031
U.S. Petent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

SUBSIDIO FAMILIA TALOF	770	Compl t if Known				
INFORMATION E	ISCLOSURE	Applicati n Numb r	09/640,041			
	BY APPLICANT		August 15, 2000	- REC E	VED	
		First Named Inventor			IVLD	
(Use as many sheets	as necessary)	Art Unit	1644	JUN 1 9	2003	
		Examiner Name	Michail A. Belyavskyi			
Sheet 1	of 1	Attorney Docket Number	59516-135 / PP-01615.002 TE	CH CENTER	1600/2900	

Examiner Initials*	Cite No.						
		PINKAS-KRAMARSKI ET AL., Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions, EMBO Jour., 1995, 15:2452-2467					
		SHELLY ET AL., Epiregulin Is a Potent Pan-ErbB Ligand That Preferentially Activates Heterodimeric Receptor Complexes, J. Biol Chem., 1998, pp. 10496-10505, 273:17					
		SEPP-LORENZINO, L. ET Al., Signal transduction pathways induced by heregulin in MDA-MB-453 breast cancer cells, Oncogene, 1996, 12:1679-1687					
		-					

Exar					
Sign				Considered	
7.5					

*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and

List of the collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.4. This collection is estimated to take 120 minutes to